| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Biomembrane Institute, Seattle 98119, and University of Washington, Seattle, Washington 98195
Sphingosine (SPN) has been claimed to be a negative modulator of transmembrane signaling through protein kinase C (PK-C) or some yet unidentified mechanism [for review see Y. A. Hannun and R. M. Bell, Science (Washington DC), 243: 500507, 1989]. N,N-Dimethylsphingosine (DMS) was recently found to be a physiological cellular component and, in comparison to SPN, to show a stronger and stereospecific inhibitory effect on PK-C activity of A431 cells (for review see Y. Igarashi, Trends Glycosci. Glycotechnol., 2: 319332, 1990; and S. Hakomori, J. Biol. Chem., 265: 1871318716, 1990). (4E)-N,N,N-Trimethyl-D-erythro-sphingenine (TMS) is not detectable as a normal cellular component; however, it is expected to exhibit potent activity because of its quaternary ammonium ion structure, and in fact it showed much stronger inhibitory effect than DMS or SPN on PK-C activity (which plays an important role in cell growth regulation) in vitro. In view of these findings, we investigated the effects of SPN, DMS, and TMS on in vitro growth of various human carcinoma cell lines and on in vivo tumor growth in athymic nu/nu mice. Both DMS and TMS showed similar in vitro and in vivo growth inhibitory effects on tumor cells, despite the fact that TMS showed a much stronger inhibitory effect than DMS on PK-C activity of A431 cells. In contrast, SPN showed only a weak effect on in vitro cell growth and no effect on in vivo tumor growth. Tumor growth following s.c. inoculation of mice with human gastric carcinoma cell line MKN74 was inhibited in a dose-dependent manner by DMS, and tumor size was decreased after three or four consecutive daily injections of 0.5-mg doses of DMS or TMS. Increased tumor growth occurred after administration of these compounds was stopped; however, size of tumor remained significantly smaller than in groups treated with SPN or control saline. The effect of DMS or TMS on in vitro or in vivo MKN74 cell growth was stronger than that of 8-chloro-adenosine-cyclic 3':5'-monophosphate dihydrate, the most promising agent currently being used in clinical trials for inhibition of tumor growth by induction of differentiation. These results suggest that DMS or TMS could be useful anticancer agents through modification of transmembrane signaling related to cancer cell growth.
1 The study was supported by the National Cancer Institute Outstanding Investigator Grant CA42505 and by funds from The Biomembrane Institute and Otsuka Pharmaceutical Co., Ltd. This study is the first in a series of related papers.
2 Present address, Department of Surgery, Tsukuba University School of Medicine, Tsukuba, Japan.
Received 10/29/90. Accepted 1/ 7/91.
This article has been cited by other articles:
![]() |
K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gundewar, J. W. Calvert, J. W. Elrod, and D. J. Lefer Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2462 - H2471. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Kim, Y. Lee, E.-J. Chang, H.-M. Kim, S.-P. Hong, Z. H. Lee, J. Ryu, and H.-H. Kim Suppression of Osteoclastogenesis by N,N-Dimethyl-D-erythro-sphingosine: A Sphingosine Kinase Inhibition-Independent Action Mol. Pharmacol., August 1, 2007; 72(2): 418 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Ghering and W. S. Davidson Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I J. Lipid Res., December 1, 2006; 47(12): 2781 - 2788. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Modrak, D. V. Gold, and D. M. Goldenberg Sphingolipid targets in cancer therapy. Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Hait, S. Sarkar, H. Le Stunff, A. Mikami, M. Maceyka, S. Milstien, and S. Spiegel Role of Sphingosine Kinase 2 in Cell Migration toward Epidermal Growth Factor J. Biol. Chem., August 19, 2005; 280(33): 29462 - 29469. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Woodcock, J. Murphy, F. C. Stomski, M. C. Berndt, and A. F. Lopez The Dimeric Versus Monomeric Status of 14-3-3{zeta} Is Controlled by Phosphorylation of Ser58 at the Dimer Interface J. Biol. Chem., September 19, 2003; 278(38): 36323 - 36327. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF] |
||||
![]() |
E. H. Ahn and J. J. Schroeder Sphingoid Bases and Ceramide Induce Apoptosis in HT-29 and HCT-116 Human Colon Cancer Cells Experimental Biology and Medicine, May 1, 2002; 227(5): 345 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Schmelz, P. C. Roberts, E. M. Kustin, L. A. Lemonnier, M. C. Sullards, D. L. Dillehay, and A. H. Merrill Jr. Modulation of Intracellular {beta}-Catenin Localization and Intestinal Tumorigenesis in Vivo and in Vitro by Sphingolipids Cancer Res., September 1, 2001; 61(18): 6723 - 6729. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. van Gijn, X. Zuidema, A. Bult, and J. H. Beijnen Protein kinase C as a target for new anti-cancer agents Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 166 - 178. [Abstract] [PDF] |
||||
![]() |
H. Vesper, E.-M. Schmelz, M. N. Nikolova-Karakashian, D. L. Dillehay, D. V. Lynch, and A. H. Merrill Jr. Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition J. Nutr., July 1, 1999; 129(7): 1239 - 1250. [Abstract] [Full Text] |
||||
![]() |
B. Campbell, Y. K. Shin, R. Scalia, and A. M. Lefer Beneficial effects of N,N,N-trimethylsphingosine following ischemia and reperfusion in the isolated perfused rat heart Cardiovasc Res, August 1, 1998; 39(2): 393 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Li, J. Manela, Y. Kong, and S. Ladisch Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts J. Biol. Chem., October 27, 2000; 275(44): 34213 - 34223. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |